Carregant...

Molecular determinants of epistasis in HIV-1 protease: Elucidating the interdependence of L89V and L90M mutations in resistance

Protease inhibitors have the highest potency among antiviral therapies against HIV-1 infections, yet the virus can evolve resistance. Darunavir (DRV), currently the most potent FDA approved protease inhibitor, retains potency against single site mutations. However, complex combinations of mutations...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biochemistry
Autors principals: Henes, Mina, Kosovrasti, Klajdi, Lockbaum, Gordon J., Leidner, Florian, Nachum, Gily S., Nalivaika, Ellen A., Bolon, Daniel N.A., Yilmaz, Nese Kurt, Schiffer, Celia A., Whitfield, Troy W.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6941756/
https://ncbi.nlm.nih.gov/pubmed/31386353
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.biochem.9b00446
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!